Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany (original) (raw)

Abstract

Background and Aims

Multiple clinical trials have demonstrated the efficacy and safety of tenofovir disoproxil fumarate (TDF) in chronic hepatitis B (CHB). However, long-term efficacy and safety data for TDF in real-life clinical practice are limited.

Methods

Prospective German field practice study in CHB-mono-infected patients. Patients were TDF-naïve but could have been treated previously with other HBV antivirals.

Results

Efficacy analysis included 400 patients; 301 (75 %) completed 36 months of TDF treatment. Both treatment-naïve and treatment-experienced patients showed a rapid decline in HBV DNA within 3 months of TDF initiation. After 36 months, HBV DNA < 69 IU/mL was achieved by 91 % of treatment-naïve patients (90 and 92 % in hepatitis B “e” antigen [HBeAg]-positive and [HBeAg]-negative, respectively) and 96 % of treatment-experienced patients (93 and 97 %, respectively). Three patients experienced virologic breakthrough, all with reported non-compliance. Overall, 5.7 % HBeAg-positive and 2.2 % HBeAg-negative patients lost hepatitis B surface antigen. Safety data were consistent with the known TDF safety profile; the most commonly reported adverse events possibly related to TDF were fatigue (2.0 %) and headache (2.0 %). Few patients (1.3 %) experienced renal-related adverse reactions. Creatinine clearance remained relatively stable over time; patients responded favorably where TDF was dose adjusted per label for decreased creatinine clearance.

Conclusions

TDF showed a favorable tolerability profile and induced rapid and sustained suppression of HBV DNA in patients with CHB treated for up to 3 years in routine clinical practice, irrespective of treatment history. Efficacy and safety in this heterogeneous patient population were consistent with data from clinical trials.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359:2442–2455.
    Article CAS PubMed Google Scholar
  2. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468–475.
    Article CAS PubMed Google Scholar
  3. Kitrinos KM, Corsa A, Liu Y, et al. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology. 2014;59:434–442.
    Article CAS PubMed Google Scholar
  4. Fung S, Kwan P, Fabri M, et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014;146:980–988.
    Article CAS PubMed Google Scholar
  5. Berg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. Gastroenterology. 2010;139:1207–1217.
    Article CAS PubMed Google Scholar
  6. Patterson SJ, George J, Strasser SI, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut. 2011;60:247–254.
    Article CAS PubMed Google Scholar
  7. Pan CQ, Hu KQ, Yu AS, et al. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. J Viral Hepatitis. 2012;19:213–219.
    Article CAS Google Scholar
  8. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology. 2011;53:62–72.
    Article CAS PubMed Google Scholar
  9. Lampertico P, Soffredini R, Yurdaydin C, et al. Four years of TDF for NUC naïve field practice European patients suppress HBV replication in most patients with a favorable renal safety profile but do not prevent HCC in patients with or without cirrhosis. Presented at AASLD, Washington DC, USA, November 1–5, 2013; poster 933.
  10. van Bömmel F, deMan RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010;51:73–80.
    Article PubMed Google Scholar
  11. van Bömmel F, de Man RA, Rutter R, et al. A European multicenter analysis of long term tenofovir (TDF) monotherapy for chronic hepatitis B in real life setting: efficacy, safety and HCC incidence. Presented at AASLD, Washington DC, USA, November 1–5, 2013; poster 941.
  12. Levrero M, Cimino L, Lampertico P, et al. OptiB—A multicenter prospective open label study on Tenofovir (TDF) for chronic hepatitis B patients with suboptimal response to adefovir (ADV) or ADV/LAM treatment. Presented at EASL, Berlin, Germany, March 30–April 3, 2011; poster 732.
  13. Lim L, Patterson S, George J, et al. Tenofovir rescue therapy achieves long-term suppression of HBV replication in patients with multi-drug resistant HBV: 5 year follow-up of the TDF109 cohort. Presented at AASLD, Boston MA, USA, November 9–13, 2012; poster 361.
  14. Peterson J, Ratziu V, Buti M, et al. Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. J Hepatol. 2012;56:520–526.
    Article Google Scholar
  15. Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in “real-life” settings: from clinical trials to clinical practice. J Viral Hepatitis. 2012;19:377–386.
    Article CAS Google Scholar
  16. Cornberg M, Protzer U, Petersen J, et al. Aktualisierung der s3-leitlinie zur prophylaxe, diagnostik und therapie der hepatitis-b-virusinfektion. Z Gastroenterol. 2011;49:871–930.
    Article CAS PubMed Google Scholar
  17. EASL. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.
    Article Google Scholar
  18. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678–686.
    Article PubMed Google Scholar
  19. Zoutendik R, Rejinders GP, Zoulim F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut. 2013;62:760–765.
    Article Google Scholar
  20. Yuan HJ, Yuen MF, Ka-Ho WD, Sablon E, Lai CL. The relationship between HBV–DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. J Viral Hepatol.. 2005;12:373–379.
    Article Google Scholar
  21. Chen CJ, Iloeje UH, Yang HI. Serum hepatitis B virus DNA as a predictor of the development of cirrhosis and hepatocellular carcinoma. Curr Hepatol Rep. 2007;6:9–16.
    Article CAS Google Scholar
  22. Heathcote EJ, Marcellin P, Buti M, et al. Three year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140:132–143.
    Article CAS PubMed Google Scholar
  23. Lock E. Sensitive and early markers of renal injury: where are we and what is the way forward? Toxicol Sci. 2010;116:1–4.
    Article CAS PubMed Google Scholar
  24. Tsai PJ, Chang A, Yamada S, Tsai N, Bartholomew ML. Use of tenofovir disoproxil fumarate in highly viremic, hepatitis B mono-infected pregnant women. Dig Dis Sci. 2014;59:2797–2803.
    Article CAS PubMed Google Scholar
  25. Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol. 2014;61:502–507.
    Article CAS PubMed Google Scholar

Download references

Funding

This study was supported by Gilead Sciences GmbH.

Author contributions

All authors were involved in data acquisition and analysis and interpretation of the data, contributed to drafting the manuscript with regards to important intellectual content and approved the manuscript prior to submission. Medical writing assistance was provided by Carol Lovegrove and Liesje Quine, Elements Communications Ltd, Westerham, UK and Jane Anderson, Chapel Hill, North Carolina, USA and funded by Gilead Sciences.

Author information

Authors and Affiliations

  1. IFI Institut für Interdisziplinäre Medizin an der Asklepios Klinik St. Georg Haus L, University of Hamburg, Lohmühlenstr 5, 20099, Hamburg, Germany
    Jörg Petersen
  2. Leberzentrum Checkpoint, Berlin, Germany
    Renate Heyne
  3. Zentrum für HIV und Hepatogastroenterologie, Düsseldorf, Germany
    Stefan Mauss
  4. Universitätsklinikum, Essen, Germany
    Jörg Schlaak
  5. Gastroenterologische Schwerpunktpraxis, Augsburg, Germany
    Willibald Schiffelholz
  6. Universitätsklinikum, Heidelberg, Germany
    Christoph Eisenbach
  7. Gastroenterologische Gemeinschaftspraxis, Herne, Germany
    Heinz Hartmann, Gisela Felten & Dietrich Hueppe
  8. Gastroenterologische Gemeinschaftspraxis, Leipzig, Germany
    Manfred Wiese
  9. Leberpraxis, Hannover, Germany
    Klaus Boeker
  10. Facharztpraxis für Innere Medizin, Wiesbaden, Germany
    Hanns-Friedrich Loehr
  11. Facharztpraxis für Innere Medizin, Berlin, Germany
    Christine John
  12. Hepatologische Schwerpunktpraxis, Offenbach, Germany
    Maria Leuschner
  13. Universitätsklinikum, Aachen, Germany
    Christian Trautwein
  14. Gemeinschaftspraxis, Stuttgart, Germany
    Andreas Trein
  15. Praxis Dr. Krause, Bayreuth, Germany
    Wolfgang Krause
  16. Gilead Sciences, Martinsried, Germany
    Susanne Ruppert & Tobias Warger

Authors

  1. Jörg Petersen
  2. Renate Heyne
  3. Stefan Mauss
  4. Jörg Schlaak
  5. Willibald Schiffelholz
  6. Christoph Eisenbach
  7. Heinz Hartmann
  8. Manfred Wiese
  9. Klaus Boeker
  10. Hanns-Friedrich Loehr
  11. Christine John
  12. Maria Leuschner
  13. Christian Trautwein
  14. Gisela Felten
  15. Andreas Trein
  16. Wolfgang Krause
  17. Susanne Ruppert
  18. Tobias Warger
  19. Dietrich Hueppe

Corresponding author

Correspondence toJörg Petersen.

Ethics declarations

Conflicts of interest

JP is an investigator and speaker/consultant for Bristol-Myers Squibb, Novartis, Roche, AbbVie and a speaker/consultant for Abbott, Boehringer, Gilead, and GlaxoSmithKline. CE is a speaker/consultant for Bristol-Myers Squibb, Gilead, Janssen, Merck Sharp & Dohme and Roche. SM is a speaker/consultant for Gilead, Bristol-Myers Squibb, Roche and Merck Sharp & Dohme. DH is on the Speakers Bureau for Gilead, Janssen, Merck Sharp & Dohme, Roche, and has served on Advisory Boards for Gilead, Janssen and Roche. KB is a speaker/consultant for Bristol-Myers-Squibb, Gilead, Roche, Merck Sharp & Dohme, Novartis, Janssen-Cilag, and Gilead. SR and TW are employees of Gilead. JS, HH, CJ, and CT, have no conflicts of interest to declare.

Research involving human participants and/or animals

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

About this article

Cite this article

Petersen, J., Heyne, R., Mauss, S. et al. Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany.Dig Dis Sci 61, 3061–3071 (2016). https://doi.org/10.1007/s10620-015-3960-x

Download citation

Keywords